Relapsed or refractory small lymphocytic lymphoma, Relapsed or refractory chronic lymphocytic leukemia research hub

HOVON 182 CLL: Prospective randomized phase 3 study of treatment with rituximab (6 cycles) in combination with 6 or 26 cycles of venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia RED RIVER CLL study: Reduced Duration Rituximab VEnetoclax in Relapsed/refractory CLL

This study looks at a new way to treat a type of blood cancer called chronic lymphocytic leukaemia (CLL) that has come back or not responded to previous treatment. It tests if a shorter course of a drug called venetoclax, combined with rituximab, works as well as a longer course.